Boston Scientific Issues Lower Q3 Results and Softens Q4 2026 Organic Revenue Guidance
Boston Scientific (BSX) reported third-quarter results that fell short of previous management guidance. Total company organic sales grew by only 1.5%, missing the initial projected range of 3% to 5%. Additionally, adjusted earnings per share (EPS) of $0.73 represented a 3% decline, trailing the expected range of $0.80 to $0.82. Looking ahead to the fourth quarter of 2026, the company has provided a cautious outlook, anticipating organic revenue growth between -3% and -1%. Management cited pressures within the Electrophysiology (EP) segment and the WATCHMAN product line, alongside cybersecurity-related headwinds, as contributing factors to the softened guidance.
Tickers: $BSX
Topics: earnings miss EPS decline financial guidance organic sales growth